Avner Reshef

Avner Reshef

Auto-generated profile, based on publicly available information

Avner Reshef


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in Allergy
Verified
Journal Article
Open access
PDF file
MMMarcus Maurer
Marcus Maurer
MMMarkus Magerl
Markus Magerl
SBStephen Betschel
Stephen Betschel
WAWerner Aberer
Werner Aberer
IAIgnacio J. Ansotegui
Ignacio J. Ansotegui
TCTimothy Craig
Timothy Craig
Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up‐to‐date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1 inhibitor (type 1) and HAE with dysfunctional C1 inhibitor (type 2), by providing guidance on common and important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on‐demand treatment and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast‐feeding women? and (5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.

25 April 2024 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
ARAvner Reshef
Avner Reshef
TBThomas Buttgereit
Thomas Buttgereit
SBStephen D. Betschel
Stephen D. Betschel
TCTeresa Caballero
Teresa Caballero
HFHenriette Farkas
Henriette Farkas
MMMarcus Maurer
Marcus Maurer

27 April 2020 in Allergy
Verified
Journal Article
Open access
MMMarcus Maurer
Marcus Maurer
WAWerner Aberer
Werner Aberer
RARosana Agondi
Rosana Agondi
MAMona Al-Ahmad
Mona Al-Ahmad
MAMaryam Ali Al-Nesf
Maryam Ali Al-Nesf
ACAnthony Castaldo
Anthony Castaldo

9 February 2021 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Open access
PDF file
GPGrzegorz Porebski
Grzegorz Porebski
MKMateusz Kwitniewski
Mateusz Kwitniewski
ARAvner Reshef
Avner Reshef
A biomarker is a defined characteristic measured as an indicator of normal, biologic, pathogenic processes, or biological responses to an exposure or intervention. Diagnostic biomarkers are used to detect a disease or a subtype of a disease; monitoring biomarkers are measured serially to assess a medical condition; response biomarkers are used to check biologic response following a medical intervention; predictive biomarkers are used to identify patients who are more likely to respond to a medical intervention; and prognostic biomarkers are used to assess the future likelihood of a clinical event. Although biomarkers have been extensively investigated and validated in many diseases and pathologies, very few are currently useful for the diagnosis, evaluation of disease activity, and treatment of hereditary angioedema (HAE). Pathophysiologic pathways involved in HAE reveal a plethora of molecules from the complement, coagulation, and fibrinolysis systems or from the vascular endothelium, which may serve as biomarkers. The most promising candidates, together with their laboratory readout systems, should be evaluated with regard to their analytical and clinical validity and utility. To be highly specific, such biomarkers should be linked to the pathomechanisms of HAE, particularly the bradykinin-generating cascade. Additionally, major advances in high-throughput omics-based technologies may facilitate the discovery of new candidate biomarkers in the future. This review will cover the existing as well as future potential biomarkers that will support the diagnosis, monitor disease activity, and can be used to assess the efficacy of new avenues of therapy of HAE and other forms of angioedema.

18 May 2021 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Open access
PDF file
AJAnkur Kumar Jindal
Ankur Kumar Jindal
ARAvner Reshef
Avner Reshef
HLHilary Longhurst
Hilary Longhurst
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of skin and mucosal edema. The main treatment goal is to enable a “normal life” for all patients. However, due to high costs, there are limited options for the management of HAE in most developing and low-income countries. As a result, most of the recommended first-line treatments are not available. In this review, we attempt to highlight the disparities in health-care resources for the management of patients with HAE amongst different countries. Data was collected from HAE experts in countries who provide tabulated information regarding management and availability of HAE treatments in their countries. We reviewed the two most recent international HAE guidelines. Using India, the world’s second most populous country, as a paradigm for HAE management in lower-income countries, we reviewed the evidence for second-line and non-recommended practices reported by HAE experts. Results suggest significant inequities in provision of HAE services and treatments. HAE patients in low-income countries do not have access to life-saving acute drugs or recently developed highly effective prophylactic medications. Most low-income countries do not have specialized HAE services or diagnostic facilities, resulting in consequent long delays in diagnosis. Suggestions for optimizing the use of limited resources as a basis for future discussion and reaching a global consensus are provided. There is an urgent need to improve HAE services, diagnostics and treatments currently available to lower-income countries. We recommend that all HAE stakeholders support the need for global equity and access to these essential measures.

7 October 2024 in Allergy
Verified
Journal Article
Open access
ARAvner Reshef
Avner Reshef
CHConnie Hsu
Connie Hsu
CKConstance H. Katelaris
Constance H. Katelaris
Philip LiPhilip Li
Philip Li
MMMarkus Magerl
Markus Magerl
TGthe VANGUARD Study Group
the VANGUARD Study Group
Background: Hereditary angioedema (HAE) is a chronic, unpredictable disease. Long‐term prophylactic treatments that offer durable efficacy, safety, and convenience are required to assist patients in achieving complete disease control, per international guidelines. We report an interim analysis of an ongoing phase 3 (VANGUARD) open‐label extension (OLE) study evaluating the long‐term safety and efficacy of garadacimab for HAE prophylaxis.Methods: Adults and adolescents aged ≥12 years with HAE previously participating in phase 2 and pivotal phase 3 (VANGUARD) studies were rolled over to an OLE, alongside newly enrolled patients. Patients received garadacimab 200 mg subcutaneously, once monthly for ≥12 months. The primary endpoint was treatment‐emergent adverse events (TEAEs) in patients with C1 inhibitor deficiency/dysfunction.Results: At data cut‐off (February 13, 2023; N = 161), median (interquartile range) exposure was 13.8 months (11.9–16.3). For the primary endpoint, 133/159 patients experienced ≥1 TEAE (524 events), equivalent to 0.23 events/administration and 2.84 events/patient‐year. Garadacimab‐related TEAEs (13% of patients, 52 events) were most commonly injection‐site reactions (ISRs). No deaths occurred. One patient discontinued treatment due to garadacimab‐related moderate ISR. Most TEAEs were mild/moderate; three events were serious (COVID‐19, two events; abdominal HAE attack, one event) and not garadacimab related. No abnormal bleeding, thromboembolic, severe hypersensitivity, or anaphylactic events were observed. Mean HAE attack rate decreased by 95% from the run‐in period; 60% of patients were attack‐free. Almost all patients (93%) rated their response to garadacimab as “good” or “excellent.”Conclusion: Garadacimab has a favorable safety profile suitable for long‐term use and provides durable protection against HAE attacks.